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Abstract
TNF receptor family members fused to the constant domain of immunoglobulin G have been widely used as
immunoadhesins in basic in vitro and in vivo research and in some clinical applications. In this study, we assemble soluble,
high avidity chimeric receptors on a pentameric scaffold derived from the coiled-coil domain of cartilage oligomeric matrix
protein (COMP). The affinity of Fas and CD40 (but not TNFR-1 and TRAIL-R2) to their ligands is increased by fusion to
COMP, when compared to the respective Fc chimeras. In functional assays, Fas:COMP was at least 20-fold more active than
Fas:Fc at inhibiting the action of sFasL, and CD40:COMP could block CD40L-mediated proliferation of B cells, whereas
CD40:Fc could not. In conclusion, members of the TNF receptor family can display high specificity and excellent avidity for
their ligands if they are adequately multimerized. Ó 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction either in the membrane-bound form and/or as solu-
ble cytokines after proteolytic processing. Their
Ligands of the tumor necrosis factor (TNF) family receptors belong to a family of type I membrane
are synthesized as homotrimeric type II membrane proteins characterized by repetitive cysteine-rich
proteins, which fulfill their biological functions modules in their extracellular domains.
Presently, 18 ligands and 22 receptors have been
described, some of which are orphans while othersAbbreviations: OPG, osteoprotegerin; TNF, tumor necrosis
factor; TNFR, TNF receptor; TRAIL, TNF-related apoptosis have one or more binding partners. Most of the
inducing ligand; CMP, cartilage matrix protein; COMP, cartilage functions executed by these systems are associated
oligomeric matrix protein; CTL, cytotoxic T lymphocyte; PA, with the immune system and are in relation with the
Protein A
control of proliferation, differentiation and apoptosis.
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apoptosis of thymocytes and mature T cells (Russell tivation-induced cell death (Suda et al., 1993;
et al., 1993; Zheng et al., 1995; Amakawa et al., Hanabuchi et al., 1994; Dhein et al., 1995; Ju et al.,
1996; Nocentini et al., 1997). Soluble TNF acts as an 1995). Furthermore, in vivo analysis was performed
inflammatory cytokine coordinating host defenses in by administration of recombinant RANK:Fc or by
response to infection (Vassalli, 1992). TRAIL/Apo- transgenic expression of lymphotoxin b receptor:Fc
2L, whose expression can be induced on peripheral (Ettinger et al., 1996; Bachmann et al., 1999).
blood T cells or on monocytes by interferons, In the field of cytokine research, the use of
mediates tumoricidal activity (Griffith et al., 1999; chimeric soluble receptors is a promising alternative
Kayagaki et al., 1999). T-cell help via CD40L/CD40 to monoclonal antibodies to create efficient in-
interaction is important for B cell survival, prolifer- hibitors: the simple fusion of receptors to an appro-
ation, immunoglobulin isotype switch and differen- priate oligomerization support yields blocking agents
tiation (Laman et al., 1996; van Kooten and Ban- with high specificity and high affinity. Soluble
chereau, 1997). Moreover, the CD40 signaling path- receptors have the potential to block unknown
way increases dendritic cell function and is therefore ligands and, when they do bind more than one
implicated in antigen-specific T-cell responses in ligand, display a specificity distinct from that of an
vivo (Grewal et al., 1995; Campbell et al., 1996). antibody.
The activity of TNF-family members can be In this study we demonstrate that the fusion of the
regulated by soluble receptors, which are either gene extracellular domains of Fas and CD40 to the
products on their own or result from proteolytic pentamerization domain of cartilage oligomeric ma-
processing of membrane-bound receptors. For exam- trix protein (COMP) (Malashkevich et al., 1996;
ple, the soluble dimeric receptor OPG favors bone Terskikh et al., 1997) enhances their inhibitory
formation by inhibiting RANKL/TRANCE/ODAF, activity towards their respective ligands as compared
which is both a survival factor for dendritic cells and with classical Fc fusion proteins.
an inducer of osteoclast differentiation and activation
(Anderson et al., 1997; Simonet et al., 1997; Wong et
al., 1997; Bucay et al., 1998; Lacey et al., 1998). 2. Materials and methods
Recombinant soluble receptors, which are classi-
cally produced as fusion proteins with the dimerizing
2.1. Materialsconstant domain of immunoglobulin G, are common-
ly used as specific inhibitors of their cognate ligands
The anti-Flag M2 monoclonal antibody and M2-(Chamow and Ashkenazi, 1996). Indeed, high-affini-
agarose was purchased from Sigma (Buchs, Switzer-ty inhibitors of TNF-family members are potentially
land). Cell culture reagents were obtained from Lifeuseful for treatment of disease where expression of
Sciences (Basel, Switzerland). Molecular weightthese ligands is disregulated. Chronic inflammation
standards for gel permeation chromatography, HiT-with elevated TNF levels leads to diseases such as
rap chelating and HiTrap Protein A columns wereCrohn’s disease or rheumatoid arthritis, and both
¨obtained through Pharmacia (Dubendorf, Switzer-conditions can been improved by the administration
land). Goat anti-mouse antibodies coupled to per-of TNF-R2:Fc alone or in combination with other
oxidase or to FITC were purchased from Jacksontreatments (Stack et al., 1997; Weinblatt et al., 1999).
laboratories (La Roche, Switzerland). Anti-CD19Ectopic expression of FasL has been shown to be
antibody was obtained through Pharmingen.involved in toxic epidermal necrolysis, a severe,
often lethal reaction to drugs that leads to massive
keratinocyte cell death. Inhibition of the Fas-FasL 2.2. Cells
system rapidly improves this condition (Viard et al.,
1998). Murine B lymphoma A20 cells were maintained in
Chimeric receptors have also been used for in DMEM containing 5% FCS and 50 mM b-mercap-
vitro studies to analyze the significance of FasL for toethanol. The human T lymphoblastoma Jurkat, the
cytotoxic T lymphocyte (CTL) function and ac- Jurkat subclone D 1.1 (kindly provided by Dr J.
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Browning, Biogen, Cambridge, MA), BJAB Burkitt 2.4. Transient transfection
lymphoma, chronic myelogenous leukemia K-562
and the murine fibrosarcoma WEHI-164 cells were 293 T cells were transfected by the CaCl method2
cultured in RPMI 1640 supplemented with 10% with previously published methods (Schneider et al.,
FCS. Stable clones of 293 cells were grown in 1997), washed with PBS and incubated for 3 days in
DMEM Nut Mix F-12 supplemented with 2% FCS. serum-free Optimem medium. Supernatants were
2 / 2Perforin and gld spleenocytes were grown in concentrated 30 times and kept frozen until use.
RPMI 1640 containing 10% FCS. All media con- Concentrations of Fas:≠N-OPG and Fas:CMP in
tained antibiotics (penicillin and streptomycin at 5 concentrated Optimem medium were determined by
mg/ml each and neomycin at 10 mg/ml) and FCS titration on Western blots using purified Fas:COMP
was heat-inactivated. Human peripheral blood lym- as a standard.
phocytes (PBL) were cultured in DMEM sup-
plemented with 10% FCS and 10 mM b-mercap- 2.5. Purification of recombinant proteins
toethanol.
Supernatants of stably transfected 293 cells were
loaded onto M2-agarose (ligands) or Protein A-
2.3. Vector constructions and establishment of cell Sepharose (Fc fusion proteins), washed with PBS
lines expressing the receptor chimeras and eluted with 50 mM citrate–NaOH pH 2.5. The
eluate was neutralized with Tris–HCl pH 8 and the
Receptor chimera were constructed in a modified buffer was exchanged to PBS in Centrikon-30 con-
PCR-3 vector (InVitrogen) as a succession of inter- centrators (Amicon, Easton, TX). COMP and CMP
changeable modules, in the following order (59 to chimeras were purified on HiTrap chelating columns.
39): (a) A HindIII /SalI module containing the ex- For this purpose, supernatants of stably transfected
tracellular domain of a receptor preceded by the 293 cells were supplemented with 500 mM NaCl and
Kozak sequence GCCACC [hTNF-R1, aa 1-211; 10 mM imidazole and were passed through the
h-TRAIL-R1, aa 1-239; hTRAIL-R2, aa 1-212; columns preloaded with 0.1 M ZnSO pH 2.5 and4
hTRAIL-R3, aa 1-240; hCD40, aa 1-193] or by 24 equilibrated in PBS. The column was washed with
nucleotides of the 59-untranslated region [hFas, aa PBS and proteins were eluted with PBS containing
1–170]; (b) a 14 amino acid linker sequence 50 mM EDTA. The buffer was exchanged to PBS as
(PQPQPKPQPKPEPE) in a SalI /XhoI cassette (Ter- described above. Flag-FasL and Flag-TRAIL were
skikh et al., 1997); (c) an oligomerization domain in produced as described previously (Schneider et al.,
a XhoI /NotI module [OPG, aa 187–401, referred to 1997; Thome et al., 1997). Flag-CD40L (aa 116–
as dN-OPG; CMP, aa 451–493 (GenBank 115555); 261) was expressed in bacteria and purified on M2-
COMP, aa 32–75 (GenBank 1705995)]; (d) a NotI / agarose as described for Flag-TRAIL. Protein con-
XbaI cassette containing a combined His -myc tag centration was determined by the bicinchoninic acid6
and a stop codon. The COMP oligomerization do- method (Pierce Chemical, Rockford, IL) using
main was flanked by aa sequences GGCC and bovine serum albumin as standard and the purity was
ARTPGGGS at the N and C-termini, respectively. assessed by SDS–PAGE and Coomassie blue stain-
The linker was present in all constructs and expres- ing.
sion in the absence of the linker has not been tested.
For Fc constructs, the hinge, CH2 and CH3 domains 2.6. Gel permeation chromatography
and the stop codon of hIgG1 were cloned as a
SalI /NotI cassette as previously described The indicated amount of recombinant protein was
(Schneider et al., 1997; Schneider et al., 1998). loaded in a total volume of 200 ml onto a Superdex
Stable HEK-293 derived cell lines for the production 200 HR 10/30 column (Pharmacia) and eluted at 0.5
of the recombinant proteins were established by ml /min in PBS with online recording of absorbance
selection in 800 mg/ml of G418 with previously at 280 nm. Fractions (0.25 ml) were analyzed in
published methods (Schneider et al., 1997). cytotoxic assays as described below. For the estima-
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tion of the molecular weight, the column was Madison, WI) assay. Absorbance was measured at
calibrated with the standard proteins thyroglobulin 490 nm. To express molar concentrations of the
(669 kD), ferritin (440 kD), catalase (262 kD), various recombinant proteins, M was estimated asr
aldolase (158 kD), bovine serum albumin (67 kD), follows: [(theoretical M 13 kDa per predicted N-r
chicken ovalbumin (43 kD), chymotrypsinogen A linked glyan)3multiplicity]. Fas:Fc, :COMP, :CMP,
(25 kD) and ribonuclease A (13.7 kD). :dN-OPG: 98, 172, 100 and 105 kDa respectively.
TRAILR2:Fc, :COMP, :CMP, :dN-OPG: 86, 142, 82
2.7. Competition ELISA and 93 kDa. TNFR1:Fc, :COMP: 104 and 187 kDa.
CD40:Fc, :COMP: 101 and 180 kDa. TRAILR2:Fc:
Ninety-six-well ELISA plates were coated with 86 kDa. TRAILR3:Fc: 127 kDa. Flag-TRAIL, Flag-
the receptor:Fc chimeras (0.2 mg/ml in PBS, 100 ml, FasL, Flag-TNFa, Flag-CD40L: 71, 55, 56 and 54
16 h, 258C). The wells were saturated for 1 h at 378C kDa respectively.
in PBS containing 5% fetal calf serum (blocking
buffer). When sCD40L was used, blocking buffer 2.9. BIAcore measurements
was PBS containing 4% fat-free milk and 0.05%
Tween-20. Competing Fc or COMP fusion proteins BIAcore measurements were carried out on CM5
were serially diluted in 100 ml of blocking buffer in carboxymethyldextran modified sensor chips (BIA-
the presence or absence of 1 mg/ml of Protein A. core AB, Uppsala, Sweden) at a flow-rate of 5
Ligands were added at constant concentration ml /min. The CM5 chips were activated with a 50-ml
(sFasL: 2 mg/ml, 36 nM, sTNFa: 0.02 mg/ml, 0.36 pulse of a 1:1 mixture of N-ethyl-N9(3-di-
nM, sTRAIL: 0.1 mg/ml, 1.4 nM, sCD40L: 0.5 methylaminopropyl)carbodiimide:N-hydroxy-
mg/ml, 9.2 nM; all in blocking buffer) and allowed succinimide. Six ml of a 100 mg/ml solution of M2
to bind for 1 h at 378C. Bound ligands were revealed anti-Flag monoclonal antibody in 10 mM NaHCO3
with M2 anti-Flag antibody (1 mg/ml in blocking pH 5.5 was then passed over the activated surface. A
buffer, 100 ml, 45 min, 378C), goat anti-mouse 50-ml pulse of 1 M ethanolamine–HCl deactivated
antibody coupled to peroxidase (1:2000 in blocking the remaining N-hydroxysuccinimide esters. The
buffer, 100 ml, 30 min, 378C) and o-phenylenediam- amount of M2 immobilized using this procedure was
ine hydrochloride (0.3 mg/ml in 50 mM citric acid, around 4600 response units. To analyze FasL-Fas-
100 mM Na HPO , 0.01% H O ). Absorbance was :chimeras and TRAIL-TRAIL-R2:chimeras interac-2 4 2 2
measured at 490 nm. tion, a constant amount of flagged ligand was
immobilized on the M2-modified surface. To achieve
2.8. Cytotoxic assays this, a 7-ml pulse of 2.5 mg/ml Flag-FasL or Flag-
TRAIL was applied to the surface. This resulted in
The cytotoxic assays were performed in 96-well binding of around 100 to 150 response units (these
plates in a volume of 100 ml essentially as described conditions allowed minimum dissociation of ligands
previously (Schneider et al., 1997). Chimeric re- from the M2 surface, while allowing sufficient
ceptors were serially diluted in medium containing subsequent receptor binding for the analysis). Bind-
the amounts of cytotoxic ligands able to induce more ing of the receptor chimera was then analyzed by
than 95% of cell death, as indicated in the figure 15-ml injections of purified receptor chimeras at
legends. Where stated, Protein A was present at 1 concentrations ranging between 1 and 100 mg/ml,
mg/ml. sFasL was always used in the presence of 1 corresponding to 100–150 response units. Associa-
mg/ml of M2 and sTRAIL in the presence of 2 tion kinetics were measured for 3 min and dissocia-
mg/ml of M2. No M2 was added in assays with tion kinetics for 3 to 5 min. The surface was
sTNFa. Cell were added for a 16 h incubation and regenerated to a plain M2 surface by a 5-ml pulse of
their viabilities were determined using the PMS/ 50 mM citrate–HCl, pH 2.5. Up to 30 successive
MTS (phenazine methosulfate /3-[4,5-dimethyl- rounds of binding and regeneration could be
thiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sul- achieved without significantly altering the binding
fophenyl]-2H-tetrazolium, inner salt) (Promega, properties of the immobilized M2 antibody. The
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dissociation and association kinetics were analyzed 2.12. Mixed lymphocyte culture
using the manufacturers kinetic analysis program,
using the AB5A1B and A1B5AB models respec- Animal care was in accordance with institutional
tively. It is noteworthy that the experimental setup guidelines. Responder spleen cells from perforin-
b
used (capture antibody) imposes a limit to the deficient or gld C57BL/6 mice (H-2 ) were cultured
measure of very high affinities. with gamma-irradiated (36 Gy) spleen cells from
dBalb /c mice (H-2 ) for 5 days. Before use, nonvi-
2.10. Culture of primary mouse hepatocytes able cells were removed from samples by a gradient
centrifugation on Ficoll-Paque (Pharmacia Biotech).
C57BL/6 mice were sacrificed by cervical dislo- The labeling was performed with previously pub-
cation, the liver lobe located above the biliary vesicle lished methods (Kataoka et al., 1998). Briefly, target
51
was immediately removed and kept in hepatocyte cells (A20) were labeled with sodium [ Cr]-chro-
attachment medium (HAM). The lobe was first mate (Dupont, Boston, MA) for 1 h, then washed
perfused with 16 ml of 10 mM Hepes pH 7.6 three times with RPMI 1640. MLC cells were mixed
4(Hepes) to remove erythrocytes and then with 12 ml with target cells (10 cells /well) in U-bottomed
of 0.5 mg/ml collagenase H (Boehringer Mannheim) microtiter plates in the presence or absence of Fas:Fc
in Hepes, 4 mM CaCl , and then homogenized in a and Fas:COMP at 40 mg/ml in a final volume of 2002
Petri dish in Hepes. The cells were washed in Hepes, ml, and the plates were centrifuged (2003g, 3 min).
then centrifuged (1003g, 30 s, no brake) and After incubating for 4 h, supernatants were removed
51
resuspended in 60% isotonic Percoll (Pharmacia) in and their radioactivity measured. Specific [ Cr]
HAM and again centrifuged (7003g, 2 min, no release (%) was calculated using the following
brake). All buffers and medium were used at 378C. formula: [(experimental release2spontaneous re-
Sedimented cells were resuspended in HAM, lease) /(maximum release2spontaneous release)]3
counted, seeded in flat-bottomed microtiter plates 100.
(10 000 per well, 200 ml) and allowed to attach for
24 h. The experimental mixture (serially diluted 2.13. FACS staining
inhibitors, sFasL (final concentration: 400 ng/ml, 7
1 5
nM) and M2 antibody (final concentration: 1 mg/ The CD40L Jurkat clone D 1.1 (5310 cells)
ml)) was added and cells were incubated for another was incubated with 2 mg of CD40:COMP in FACS
16 h. The supernatant was taken off, fresh HAM buffer (PBS, 10% fetal calf serum and 0.02% NaN ).3
(100 ml) was added and the viability assay PMS/ Fas:COMP was used as a negative control. Re-
MTS was performed as described under cytotoxic ceptor:COMP were detected with 1 mg of 9E10
assays. anti-myc antibody followed by FITC-labeled goat
anti-mouse antibody (1:100). Incubations were per-
2.11. Activation-induced cell death formed for 20 min at 48C in 50 ml of FACS buffer.
Flat-bottom microtiter plates were coated with 2.14. B-cell proliferation assay
anti-human CD3 TR66 (10 mg/ml) in PBS for 3 h at
1378C. Plates were washed twice with PBS and once CD19 cells were purified from human peripheral
5
with RPMI 1640 medium. Jurkat cells (5310 cells blood lymphocytes (PBL) with magnetic beads and
2per ml, 100 ml) were mixed with the inhibitors as the remaining CD19 cells were irradiated (3000
5 1 5indicated in the figure legend and distributed to each rads). 10 purified CD19 cells were mixed with 10
2
well, then centrifuged (2003g, 3 min) and incubated CD19 autologous irradiated PBL in 120 ml of
for 24 h at 378C. Cell viability (OD490) was medium containing sCD40L at 100 ng/ml (1.8 nM)
measured as described for cytotoxic assays. Specific M2 antibody at 10 mg/ml plus or minus Protein A at
cell protection (%) was calculated as follows: [(anti- 1 mg/ml and the indicated concentrations of
CD3 1 inhibitor) 2 (anti - CD3)] / [(control) 2 (anti - CD40:Fc or CD40:COMP. Cells were then cultured
CD3)]3100. for 72 h in 96-well plates, pulsed for 6 h with
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3 3[ H]thymidine (1 mCi/well) and harvested. [ H]thy- FasL (sFasL), although the level of protection (up to
midine incorporation was monitored by liquid 50%) was extremely low considering that the esti-
scintillation counting. mated molar ratio of Fas:Fc to FasL was as high as
1000 in the assay (Fig. 1a, lower panel). A weak
protecting activity was observed in some of the early
3. Results fractions of the elution, which was probably due to
minute, undetectable amounts of high molecular
3.1. Aggregation of chimeric Fas:Fc receptor weight complexes of Fas:Fc. This latter observation
increases its specific activity suggested that aggregates of the fusion protein could
be potent inhibitors of FasL-induced cell death, and
Chimeric proteins consisting of the extracellular we therefore attempted to increase this high molecu-
domains of a receptor fused to the Fc portion of an lar weight fraction by aggregating Fas:Fc with the
IgG (receptor:Fc) have been widely used as inhib- immunoglobulin cross-linking agent Protein A. When
itory agents to investigate receptor–ligand interac- the analysis was repeated under conditions where
tions. We examined the homogeneity in size of about 10% of the injected Fas:Fc was shifted to the
purified Fas:Fc by size exclusion chromatography early eluting fractions (Fig. 1b, upper panel), it was
and found that it eluted as a single peak with the clear that the high molecular weight Fas:Fc was an
expected retention time (Fig. 1a, upper panel). efficient antagonist of FasL cytotoxicity, whereas the
Fas:Fc-containing fractions were able to partially remaining Fas:Fc that still eluted as a dimer only
protect A20 cells exposed to a lethal dose of soluble conferred partial protection to cells despite its ten-
Fig. 1. Aggregation of Fas:Fc potentiates its inhibitory activity. Panel A (upper half): Superdex-200 elution profile of purified Fas:Fc (100
mg) monitored at 280 nm. The elution position of molecular weight standards are indicated (in kDa). Panel A (lower half): Protection assay
against FasL-induced cell death of A20 cells. Aliquots (10 ml) of each 250-ml fraction were transferred to A20 cells treated with 100 ml of
sFasL at 0.18 nM. Panel B: Same as panel A, except that 100 mg of Fas:Fc and 10 mg of Protein A were simultaneously loaded on the
Superdex-200 column.
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fold higher concentration (Fig. 1b, lower panel). affinity on metal-chelating columns or on Protein-A
Taken together, these results indicate that the forma- (Figs. 2, 3a and b). Fas and TRAIL-R2 were also
tion of Fas:Fc aggregates substantially increases its joined to the C-terminal dimerization domain of the
specific activity. TNF family member osteoprotegerin (Receptor:≠N-
OPG) (Yamaguchi et al., 1998).
3.2. Construction of novel oligomeric chimeras of Receptors fused to COMP or CMP clearly oligo-
TNF receptor family members merized, as indicated by their slow migration in
polyacrylamide gels under non-reducing conditions
We reasoned that an increase in the oligomeriza- (Fig. 3b). Fas:COMP and TRAIL-R2:CMP eluted as
tion status of Fas should result in a better avidity defined peaks with apparent molecular masses of
towards FasL and thus possibly improve its inhib- approximately 400 and 170 kDa by gel permeation
itory properties. Therefore, we constructed fusion chromatography, which are compatible with penta-
proteins in which the extracellular domains of Fas, meric and trimeric structures, respectively (Figs. 3c
TRAIL-R1, TRAIL-R2, TRAIL-R3, TNF-R1 and and d). Therefore, we can conclude that the aggrega-
CD40 were fused via a 14 amino acid linker to the tion properties of the coiled-coil oligomerization
oligomerizing domains of either the cartilage oligo- domains are not impaired by fusion to members of
meric matrix protein (receptor:COMP) or the cartil- the TNF receptor family.
age matrix protein (receptor:CMP). These cartilage
matrix proteins have been shown previously to form 3.3. Fas:COMP is a more efficient competitive
pentameric and trimeric coiled-coil structures, re- inhibitor of sFasL than Fas:Fc and has a lower
spectively (Hauser and Paulsson, 1994; Malas- dissociation constant
hkevich et al., 1996; Wiltscheck et al., 1997). The
novel fusion proteins, as well as receptor:Fc controls, Fas:COMP displayed a lower K than Fas:FcD
were expressed in mammalian cells and purified by when the chimeras were allowed to compete for
Fig. 2. Schematic representation of the oligomerized soluble receptors described in this study. Soluble receptors were dimerized, trimerized
or pentamerized by fusion with the C-terminal domain of OPG, the coiled-coil domain of CMP and the coiled-coil domain of COMP,
respectively.
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Fig. 3. Characterization of chimeric receptors. Panels A and B: Coomassie Blue staining of various chimeric receptors (8 mg) under
reducing (1) or non-reducing (2) conditions. Panel C: Size exclusion chromatography of Fas:COMP (50 mg). Protection assay against
sFasL-induced cell death was performed on A20 cells as described in the legend to Fig. 1. Panel D: Size exclusion chromatography of
TRAIL-R2:CMP (50 mg). Protection assay against TRAIL-mediated cell death was performed on Jurkat cells treated with 1.4 nM of
sTRAIL.
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sFasL binding to coated Fas:Fc (Fig. 4a). In accord- competition ELISA, an important increase in affinity
ance with this result, we measured a dissociation (30 fold) was observed for the pentamerized re-
constant of 0.77 nM for the sFasL-Fas:COMP inter- ceptor, whereas the effect was intermediate for
action, which is around eight to nine times lower CD40:Fc /PA (eight fold) (Fig. 5a). We next won-
than that found for Fas:Fc (Table 1). On the majority dered whether CD40:COMP could also recognize
of the cell lines tested, the inhibitory activity of membrane-bound CD40L. To this purpose, we used
Fas:COMP was approximately ten- to 20-fold higher the Jurkat-derived cell line D1.1 that constitutively
than that of dimeric Fas:Fc, whereas that of Fas:Fc expresses surface CD40L, to perform FACS staining
aggregated in the presence of Protein A (Fas:Fc /PA) analysis using CD40 chimera as a probe. A signifi-
was intermediate (Fig. 4b, 4e and data not shown). cant staining was observed with CD40:COMP in-
Two cell lines (the murine A20 B lymphoma and the dicating that CD40:COMP was indeed able to bind
human BJAB Burkitt lymphoma), although efficient- to native, unprocessed CD40L (Fig. 5b). To test the
ly protected by Fas:COMP, were not or only very activity of the CD40 chimeras in a biological system,
inefficiently protected by Fas:Fc (Fig. 4c), even in we attempted to inhibit the CD40L-dependent prolif-
the presence of a 20-fold excess of an irrelevant eration of human B cells costimulated with anti-B
receptor:Fc (Fig. 4d). cell receptor. Neither CD40:Fc nor CD40:Fc /PA
As expected, the activity of the dimeric Fas:≠N- could significantly prevent proliferation, even when
OPG was similar to that of Fas:Fc (Fig. 4e). Trimeric they were administered at high doses. In contrast,
Fas:CMP inhibited sFasL-mediated lysis as efficient- CD40:COMP efficiently blocked proliferation, al-
ly as Fas:Fc /PA but was about five times less ready at relatively low doses (Fig. 5c).
effective than Fas:COMP (Fig. 4e). The inhibitory
activity of Fas:COMP was as good or better than that
of FasL-blocking mAb Nok-1, 4H9 and 4A5 3.5. Increased affinity of soluble chimeric
(Kayagaki et al., 1995; Tanaka et al., 1996). receptors of the TNF-receptor family is not a
The superior inhibitory activity of Fas:COMP general phenomenon
compared to Fas:Fc was also evident on primary
mouse hepatocytes (Fig. 4g) or in a model system When the binding of the TRAIL-R2:Fc and
for activation-induced cell death using anti-CD3 TRAIL-R2:COMP to sTRAIL was compared in the
activated Jurkat cells (Fig. 4h). In all experiments, competition ELISA assay, no significant differences
Fas:Fc /PA yielded an intermediate level of protec- in the affinities could be observed (Fig. 6a). In
tion. We next tested whether Fas:COMP would addition, the dissociation constants of the interac-
inhibit FasL expressed by CTLs. Killing of A20 cells tions of TRAIL with TRAIL-R2:COMP or TRAIL-
in a 4-h assay depends uniquely on perforin and R2:Fc were not significantly different (Table 1).
FasL-dependent pathways, as CTLs deficient for These results are confirmed in a TRAIL inhibition
both perforin and FasL have no effect on these cells assay on various cell lines, where all TRAIL-
(Braun et al., 1996). As expected, A20 cells were R2:chimeras were equally efficient (Fig. 6b and c).
killed by both perforin-deficient CTLs and FasL- The same conclusion was obtained with TRAIL-R1,
deficient CTLs (Fig. 4i). Fas:Fc and Fas:COMP TRAIL-R3 and OPG, because their inhibitory ac-
specifically conferred some protection to cells ex- tivities could not be increased upon aggregation with
posed to perforin-deficient CTLs (Fig. 4i). Surpris- PA (Fig. 6d and data not shown). We also tested the
ingly, there was no difference between Fas:Fc and efficiency of various TNF-R1 chimeric proteins at
Fas:COMP and both inhibitors were partially active competing with TNFa binding to coated TNF-R1:Fc
only when utilized at relatively high concentrations. and at inhibiting the cytotoxic effect of sTNFa. No
differences were observed between TNF-R1:Fc,
3.4. CD40:COMP is a potent inhibitor of CD40L TNF-R1:Fc /PA and TNF-R1:COMP (Fig. 6e and f).
These results indicate that increased oligomerization
When the affinities of sCD40L to CD40:Fc, is beneficial for the activity of some but not all
CD40:Fc /PA or CD40:COMP were compared by members of the TNF receptor family.
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Table 1
Binding constants for the interaction of Flag-FasL and Flag-TRAIL with the Fc or COMP fusion protein of Fas and TRAIL-R2, respectively
4 -1 21 24 21Receptor:chimera k 310 (M s ) k 310 (s ) K (nM)on off D
Fas:Fc 3.460.84 2.360.55 6.761.4
Fas:Comp 8.261.6 0.6360.12 0.7760.14
Trail-R2:Fc 34.0614 1.460.43 0.4160.08
Trail-R2:Comp 15.060.42 1.060.28 0.6760.18
Fig. 5. CD40:COMP inhibits sCD40L. Panel A: Competition ELISA. CD40:Fc, CD40:Fc/PA or CD40:COMP were allowed to compete for
1
sCD40L with coated CD40:Fc. Panel B: Staining of surface-expressed CD40L. The CD40L Jurkat cell line D 1.1 was stained with either
CD40:COMP or Fas:COMP as a control, and analyzed by FACS. Panel C: Inhibition of CD40L-dependent B-cell proliferation by
CD40:COMP. CD191 purified human PBLs were co-incubated with irradiated autologous CD19-PBLs and stimulated for 72 h with
3
sCD40L in the presence of the indicated amounts of inhibitors. Results are expressed as percent of [ H]-thymidine incorporation in the
3
absence of inhibitors ([ H]-thymidine incorporation was 25 000 cpm in the absence of Protein A and 20 000 cpm in the presence of Protein
A. Background incorporation was 700 cpm).
4. Discussion fully exploit the avidity potential inherent in the
structure of the ligands. Cross-linked ligands, which
Ligands of the TNF-family are trimeric and allow often display enhanced activity (Schneider et al.,
the binding of up to three receptors at their mono- 1998), offer even more sites for high avidity receptor
mer–monomer boundaries (Banner et al., 1993). binding. We have constructed fusion proteins of
Recombinant dimeric receptors can therefore not various receptors to different dimeric (≠N-OPG),
Fig. 4. Binding of Fas to soluble and membrane-bound FasL is increased by oligomerization. Panel A: Competition ELISA. Soluble Fas:Fc,
Fas:Fc /PA or Fas:COMP were allowed to compete with coated Fas:Fc for sFasL. Panels B and C: Titration of the inhibitory activity of
Fas:Fc, Fas:Fc /PA and Fas:COMP. sFasL was used at concentrations of 0.9 nM (on Jurkat, BJAB and A20 cells) and 3.6 nM (on WEHI 164
cells). Panel D: The low activity of Fas:Fc on BJAB cells is not dependent on the Fc portion of the molecule. The experiment was performed
as described in panel C, except that increasing amounts of TRAIL-R2:Fc (mock:Fc) were added. Panel E and F: Titration of the inhibitory
activity of Fas chimeras and of the anti-FasL Nok-1 antibody. Jurkat cells were treated with sFasL at 7.2 nM (eight-fold higher concentration
than that used in panel B). Panel G: Fas:COMP protects primary mouse hepatocytes from FasL-induced death. Hepatocytes were cultivated
in the presence of 7.2 nM of sFasL. Panel H: Inhibition of activation-induced cell death (AICD) of Jurkat cells. Cells were exposed to coated
anti-CD3 antibody in the presence of the indicated concentrations of Fas:Fc, Fas:Fc /PA and Fas:COMP. Protection is expressed as viability
increase in the presence of inhibitors. In this model, up to 40% of cell death can be induced, about half of which can be inhibited with
Fas:Fc /PA at saturating conditions (Kataoka et al., 1998). Panel I: Inhibition of FasL-dependent CTL activity by Fas:Fc or Fas:COMP.
2 / 2 51CTLs from perforin and gld mice were activated in a mixed lymphocyte culture (MLC) and cocultivated with [ Cr]-labeled A20 cells.
51[ Cr] release in the supernatant was quantified after 4 h.
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Fig. 6. Binding of TRAIL-receptors and TNF-R1 to their respective ligands is not increased by oligomerization. Panel A: Competition ELISA. Soluble TRAIL-R2:Fc,
TRAIL-R2:Fc/PA or TRAIL-R2:COMP were allowed to compete for sTRAIL with coated TRAIL-R2:Fc. Panel B: Titration of the inhibitory activity of TRAIL-R2:Fc,
TRAIL-R2:Fc/PA, TRAIL-R2:CMP and TRAIL-R2:COMP. sTRAIL was used at concentrations of 22 nM (BJAB), 5.6 nM (Jurkat) or 2.8 nM (K-562). Panel C: Titration of the
inhibitory activity of TRAIL-R2 chimers. Jurkat cells were treated with sTRAIL at 2.8 nM. Panel D: The inhibitory activity of TRAIL-receptors:Fc is not increased by Protein A.
Conditions were as described in panel C. Panel E: Competition ELISA. Soluble TNF-R1:Fc, TNF-R1:Fc/PA or TNF-R1:COMP were allowed to compete for sTNFa with coated
TNF-R1:Fc. Panel F: Titration of the inhibitory activity of TNF-R1:Fc, TNF-R1:Fc/PA and TNF-R1:COMP. WEHI 164 cells were treated with sTNFa at 0.35 nM.
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trimeric (CMP), or pentameric (COMP) oligomeri- consistent with the relatively high dissociation con-
zation supports and have compared them to re- stant that we have measured between Fas:Fc and
ceptor:Fc fusion proteins. Inhibition of sFasL-in- FasL (7 nM) and that reported for CD40L and
duced apoptosis by these competitive inhibitors CD40:Fc (10–20 nM) (Hermann et al., 1993). By
increased as a function of their oligomerization level, comparison, the KD between monomeric TNF-R1
and the relative activities of the various inhibitors and TNFa is as low as 0.59 nM (Corti et al., 1994),
(expressed as the ratio of their respective IC ) and is close to 10 pM for TNFa and TNF-R1 on50
remained relatively constant when measured on cells at 378C (Grell et al., 1998). Thus, binding of
several cell lines. The increased inhibitory efficiency dimerized high affinity receptors to their ligands can
of Fas:COMP as compared to Fas:Fc is the likely probably be considered as nearly irreversible. Further
result of its higher avidity. aggregation of these receptors would therefore not
We identified three cases (BJAB, A20 cells and result in a significant improvement of their inhibitory
primary mouse hepatocytes) in which Fas:Fc largely activities.
or completely failed to block FasL for reasons that Our results show that dissociation constants in the
are unexplained. Under the same conditions, Fas- lower nanomolar range can be obtained for those
:COMP efficiently blocked FasL, indicating that it is receptors such as Fas and CD40, which display
not only a more potent but also a more reliable intermediate affinity for their ligands, provided that
inhibitor. they are multimerized. The affinities obtained are
Fas:COMP was more efficient than Fas:Fc at above those usually observed for monoclonal anti-
blocking apoptosis mediated by membrane-bound bodies, and we could indeed show that Fas:COMP is
FasL in a model of activation-induced cell death, but an equally or more potent inhibitor of sFasL than
both reagents only partially blocked FasL-induced NOK-1 and other widely used FasL-blocking anti-
apoptosis mediated by CTLs. CTL action depends on bodies.
both a close and tight contact with the target cell and
on a transient and polarized activation of the cytotox-
ic machinery at the docking site (Bossi and Griffiths, Acknowledgements
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